Supplementary Figure S2 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Supplementary Figure S2. MYC level in cancer cell lines and its correlation with 6K465 sensitivity. (A) Expression profiles of c-MYC and N-MYC mRNAs in various cancer cell lines retrieved from the cancer cell line encyclopedia (CCLE) repository. A cut-off level at 6.2 was set for c-MYC and, and a cut-off level at 0 was set for N-MYC. (B-C) Summary of genomic and molecular features, half-proliferation inhibition concentration (IC50) of 6K465 and c-MYC/N-MYC protein levels in eleven SCLC (normalized to NCI-H841) and sixteen BC (normalized to HCC1143) cell lines.